Moderna launches clinical trial for Bundibugyo's ebolavirus vaccine

Moderna has announced the start of a Phase 1 clinical trial for its investigational mRNA-1469 vaccine, designed to prevent disease caused by Bundibugyo ebolavirus (BDBV). No vaccine is currently approved for this specific strain. The trial is being conducted in Canada in partnership with the Coalition for Epidemic Preparedness Innovations (CEPI).

Thanks to mRNA technology developed during the COVID-19 pandemic, Moderna is adopting a rapid and efficient research method. The study includes approximately 80 healthy adult participants and explores the safety and immune response of the vaccine.

The program provides financial support from CEPI, up to $50 million, for preliminary trials and potential expansion to phase 2 and 3 studies. If the results are positive, Moderna ensures rapid access to affected countries, with an initial commitment of 500,000 doses.